StockWatch
·

Nephrocare Health Services Ltd Q2 FY27 Results

NEPHROPLUSQ2 FY27 Results
Filing
Result:Good· Market: Flat#Turnaround#Debt reduction#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)
Revenue303.40
Total Income311.39
Expenditure267.07
PBT44.33
Net Profit33.53
OPM22.12%
NPM10.77%
EPS3.34
View full financials

Revenue grew a strong 23.5% YoY beating guidance and PAT swung to profit, but the swing is almost entirely IPO-linked deleveraging (finance costs collapsed) while underlying operating margin ex-finance-costs actually eased to ~15.2% from ~17.8%, so quality is capped below very_good.

NEPHROPLUS · Q2 FY27 · THE VERDICT

Growth held, but margin squeeze and Saudi binary await

NephroPlus delivered 23.5% revenue growth and reaffirmed 15–20% CAGR guidance—but Q2 profit leans on adjustments not fully itemized. The real story is margin compression in new geographies and a February 2027 tender that could swing ₹15+ Crore of capex.

12 Nov 2026 · 6 min read
Q2 Revenue

₹303.4 Cr

+23.5% YoY, on guidance

Q2 Reported PAT

₹33.5 Cr

NPM 10.8%

H1 Adjusted PAT

₹76.1 Cr

13% margin, +35% YoY

EBITDA Margin (H1)

23%

vs 23.8% FY26; −80 bps YoY

NephroPlus posted a textbook guidance hit: Q2 revenue ₹303.4 Cr aligned with +23.5% growth flagged on the call, and management reaffirmed the 15–20% multi-year CAGR without change. But beneath the surface, the quarter is a study in timing: reported profit ₹33.5 Cr masks a richer underlying run (adjusted PAT ₹76.1 Cr H1, +35% YoY), margin compressed by 80 basis points despite a higher-priced international mix now at 47% of revenue, and the company's most important catalyst—a Saudi Arabia Ministry of Health tender—flips to a decision in February 2027. The stock has digested this: down 20.6% from its all-time high, FII positions trimming. The question is whether the margin squeeze is temporary (investment phase, listing costs) or structural.

Where the margin went

The 80 basis point margin compression—from FY26 YE's 23.8% to H1 FY27's 23%—is the quarter's most scrutinized line. On paper, it shouldn't exist: international revenue jumped to 47% of the mix (up from 42%), commanding ₹8,200 per treatment versus India's ₹2,785. Higher price per unit should widen margin. It didn't, and analysts pressed hard.

Despite improving international mix, why hasn't margin expanded? What's driving the 80 bps compression?

Management's answer: private-to-listed transition. Quarterly audits, ECL provisioning (new regulatory requirement), legal and tax due diligence, listing-related costs. But there's more. COGS improved 95 basis points to 22% of revenue; professional fees dropped 83 bps. The offset came from elsewhere: "other expenses" rose 160 bps—driven by new-geography rollouts (Kazakhstan Almaty clinics ramping, Saudi Arabia home dialysis & clinic in Riyadh, capex in both pre-revenue or early-ramp), forex headwinds (Uzbek som appreciated 10% vs rupee, a tailwind, but Egypt and other emerging-market ops absorbed currency volatility), and ECL provisioning. Core operations are intact; the margin hit is investment-phase and regulatory.

Management's claims vs. what holds up

Q2 revenue ₹303 Cr, +23.5% YoY

Delivered ₹303.4 Cr; +23.5% YoY confirmed

Supported

15–20% CAGR guidance maintained over 3–4 years

Reaffirmed on the call; no change from prior year

Supported

H1 EBITDA margin 23%, adjusted PAT margin 13%

H1 EBITDA ₹134 Cr / ₹585 Cr rev = 23% ✓; Adjusted PAT ₹76.1 Cr / ₹585 Cr = 13% ✓

Supported

Margin compression ~80 bps is temporary; will recover as new geographies mature

Compression confirmed (FY26 YE 23.8% → H1 FY27 23%). Recovery timeline and magnitude not specified.

Partial; transparency gap

India clinic platform at 75% utilization with room to grow

500 clinics, 75% utilization, target 40–50 annual net adds. Room exists, but Q2 net adds only 13 (vs 40–50 run rate)

Partial; execution questions

Saudi Arabia Ministry tender: 1 of 12 qualified global bidders, 11,720 patients

Tender released. NephroPlus holds 1 clinic + home dialysis in Saudi (pilot validation). Tender decision Feb 2027.

Supported; binary outcome pending

What changed on this call

  • International revenue mix jumped to 47% of total (up from 42% FY26). RPT ₹8,200 vs India ₹2,785. Validates diversification strategy but reveals why margin hasn't expanded (investment capex, ramp costs in Saudi & Kazakhstan offset higher prices).

  • Saudi Arabia Ministry of Health tender formally released (11,720 patients, 4 clusters, 12 global bidders). NephroPlus 1 of 12. Decision Feb 2027. Binary outcome: if won, ₹15–20+ Cr capex swing; if lost, capex scales back dramatically.

  • Kazakhstan Almaty acquisition (2 clinics) now in ramp phase; management guided 18–24 months to stabilization. Early-stage loss provision contributing to adjusted/reported gap.

  • NIDA (Nurse Academy) launched to solve global renal nurse shortage. Early-stage (100–200 nurses target). Strategic for international rollout but not a near-term margin driver.

  • India clinic net adds slowed to 13 in Q2 (vs 40–50 annual target), attributed to focus on ramp (75% utilization) over greenfield expansion. PPP contracts (Haryana, Tamil Nadu, Bihar) steady, but capex allocation shifting.

  • Philippines grew +11 clinics H1 (total 55); second-largest market. But competition intensifying (Diaverum global #3 entering, local fragmentation = 500+ small players). Pricing power stable but under watch.

The bull-bear ledger

  • Revenue growth 23.5% YoY sustained; 15–20% CAGR reaffirmed over 3–4 years without retreat. Guidance hit is rare in a listed transition.

  • Adjusted PAT H1 +35% YoY (₹76.1 Cr); organic profit momentum strong despite margin compression. Core operations healthy.

  • India platform solid: 500 clinics, 33,000+ guests, 75% utilization, room for organic ramp. Largest market, most predictable cash generator.

  • International diversification working: 47% of revenue now from higher-priced geographies (Philippines 55 clinics, Uzbekistan stable, Saudi/Kazakhstan entry). RPT 3x India.

  • Reported PAT ₹33.5 Cr leans on adjustments not granularly itemized (~₹42.6 Cr gap for H1 flagged as Saudi JV loss, forex, ECL, listing costs). Earnings quality concern; investor transparency gap.

  • EBITDA margin compressed 80 bps YoY despite higher-priced mix; recovery timeline vague. If ramp-up slower than guided (Kazakhstan 18+ months, Saudi post-tender), margin could stay pressured into FY28.

  • Saudi Arabia tender is binary (win/loss). ~50% implied odds (not quantified); Feb 2027 decision. Loss would derail capex plans and international momentum. Win uncertain enough that management said 'by no means can assure you.'

  • India outsourcing adoption slow (20% organized market vs 80% fragmented). Management expects 20% → 30% over 5 years—evolutionary, not inflectional. Limits near-term clinic rollout acceleration.

  • Philippines competition from Diaverum (global #3) and local fragmentation (500+ small players). Pricing power stable but market share defense required.

  • Nurse supply constraint structural globally; NIDA early-stage solution. If nurse pipeline doesn't materialize, Saudi & Kazakhstan ramp could face staffing bottleneck.

Risks, ranked by how much they should concern a holder

Saudi Arabia tender binary outcome (Feb 2027 decision pending)

High

NephroPlus is 1 of 12 global bidders for 11,720 patients. Win probability ~50% (implicit; not quantified by management). Loss derails ₹15–20+ Cr capex deployment and international growth optionality. Win upside would validate Saudi as a material revenue/margin contributor by FY28+.

Margin recovery timeline vague; new-geography ramp-up could extend pressure

High

H1 margin 23% vs FY26 YE 23.8% (80 bps compression). Management called it 'temporary investment phase' but gave no recovery timeline. Kazakhstan stabilization 18+ months, Saudi post-tender timing unknown, listing costs ongoing. If margin stays at 23% through FY27–FY28, at-risk profile for valuation multiple (especially if EPS growth stalls).

Adjusted vs reported profit gap (₹42.6 Cr H1) not granularly itemized; opacity on one-time items

Medium

Q2 reported PAT ₹33.5 Cr (NPM 10.8%) vs underlying business run rate suggests large adjustments. Management cited Saudi JV loss, forex, ECL, listing costs but didn't quantify each line. Investors left inferring the gap; risk of earnings surprise if one-time items recur or were underestimated.

India clinic net adds slowed (13 in Q2 vs 40–50 annual target); refocus on ramp over expansion

Medium

Management attributed to utilization ramp priority (75% target still underused) vs greenfield expansion. But if PPP contract sequencing slows or capex allocation to international competes harder, India organic growth could lag near term. 40–50 guidance holds, but quarterly lumpiness may persist.

Philippines competition intensity rising; Diaverum (global #3) + 500+ local fragmented players

Medium

NephroPlus 55 clinics (second-largest in Philippines). Diaverum has 30+ countries, global scale, pricing power. Local competitors 500+ small. Dialyzer pricing flat (stable input cost), but if competition escalates, clinic margins & market share could erode. NephroPlus brand established but not immune.

India outsourcing adoption structural bottleneck; slow 5-year pace (20% → 30%)

Medium

Organized dialysis market ~20% in India. Fragmented base 80% (small operators, hospital in-house units). Hospitals resist outsourcing (control, department P&L opacity). Management expects 5-year evolution to 30% organized. If adoption remains slower or stalls, clinic rollout acceleration limited; India growth capped to organic clinic adds + ramp.

Nurse supply constraint globally; NIDA early-stage and unproven

Low–Medium

Renal nurse shortage is real (management flagged as 'constraint on international expansion'). NIDA targets 100–200 nurses from Philippines/India for global deployment. Early-stage; if supply pipeline doesn't materialize, Saudi & Kazakhstan ramp could face staffing bottleneck and cost inflation.

How the street is reading this

The stock sits at ₹620.55 (as of Nov 12, 2026), down 20.6% from its all-time high of ₹781.4 and trading between its 52-week lows and above its 200-day average (₹623.28). RSI is neutral at 46.9, and volume is normal. The drawdown likely reflects two forces: listed-company overhead (quarterly audits, listing costs), margin compression (investors initially hoping 47% international mix would expand EBITDA, but ramp capex and ECL offset the price upside), and Saudi binary uncertainty (until Feb 2027 clarity, capex plans are contingent).

FII positioning has weakened: FII holdings fell from 9.94% (FY26 Q4) to 8.78% (FY27 Q1)—a trim of 116 basis points. DII held steady (+40 bps). Promoter stake unchanged at 63.85%. The FII outflow suggests foreign money is waiting for Saudi clarity or margin stabilization before re-entering.

Block/bulk deals show mixed signals: Polar Capital Healthcare Opportunities Fund accumulated ₹25.45 Crore at ₹705.00 (large strategic buy), but Edoras Investment Holdings PTE LTD (a Singapore vehicle, likely promoter-linked or strategic partner) sold ₹8.42 Crore twice at ₹710.45 and ₹710.18 (near the highs). Mansi Share & Stock Broking showed mixed activity (bought ₹8.23 Cr @ ₹705.24, sold ₹8.16 Cr @ ₹710.45). The pattern suggests profit-taking near ₹710 and value accumulation around ₹705. Institutional buyers (Polar Capital) stepping in at depressed levels is a mild positive signal; foreign exit (Edoras) near highs is cautionary.

Overall street read: Hold, not sell. The margin compression and Saudi binary are real, but the company hit guidance, reaffirmed CAGR, and delivered 35% adjusted PAT growth. The stock has repriced from the high, making it less frothy. Foreign money waiting; domestic buying on the dip suggests some confidence in medium-term rebound (post-Saudi clarity, margin stabilization).

The debate

What to watch next
  • 1 · Saudi Arabia Ministry tender decision (Feb 2027)

    Binary outcome. Win = ₹15–20+ Cr capex deployment, FY28 revenue acceleration, Saudi as material center of gravity by FY29. Loss = capex scaled, international growth optionality curtailed. This is the single most important event for FY27–FY28 re-rating.

  • 2 · Margin stabilization path (FY27 H2 + FY28)

    Watch for EBITDA margin recovery from 23% toward 24%+ as new-geography capex-to-revenue ratios normalize (Kazakhstan breakeven, Saudi post-tender ramp, listing costs amortize). If margins stay at 23% through FY28, growth story loses momentum. If they recover to 24%+ by FY28, growth + margin expansion narrative re-emerges.

  • 3 · India clinic utilization & net adds trajectory

    India remains the cash engine (75% utilization). Monitor quarterly clinic net adds (target 40–50 annually). If adds accelerate back to 20/quarter and utilization moves toward 80%+, India organic growth is on track. If adds stay lumpy (13 in Q2) and utilization plateaus, clinic rollout might be self-limiting (capex competing with international).

  • 4 · Adjusted vs reported PAT reconciliation

    Investors should ask management for a granular breakdown of the ~₹42.6 Cr H1 adjustment gap (Saudi JV loss, forex, ECL, listing costs, each quantified separately). Lack of clarity here is a credibility drain. Expect clarification by Q3 FY27 or annual report filing.

  • 5 · Philippines competitive positioning & clinic economics

    NephroPlus is second-largest (55 clinics) but facing Diaverum (global #3) and 500+ fragmented locals. Monitor clinic-level economics (margin, utilization) and market share trends. If pricing power erodes or clinic adds slow, Philippines story weakens.

The bottom line

NephroPlus delivered a steady quarter: revenue growth 23.5% on guidance, 15–20% CAGR reaffirmed, adjusted PAT +35% YoY. But steady is not exciting, and the quarter is defined by what's not expanding—margins, despite a higher-priced international mix at 47% of revenue. The margin hit is explained (investment capex, listing costs, ECL) but recovery is contingent and timeline vague. The stock has repriced down 20.6% from highs, and foreign money is trimming (FII -116 bps), but selective buyers (Polar Capital) are accumulating at ₹705 levels, suggesting some conviction in the medium term.

The real story is February 2027: Saudi Arabia Ministry of Health tender decision. Win, and capex/growth optionality unlocks for FY28+. Lose, and the company grinds at 15–20% organic growth in a margin-compressed state—less exciting. Until Saudi clarity, the stock likely oscillates between ₹600–650. Holders should be comfortable waiting; the fundamentals are intact, but re-rating is contingent on margin stabilization + Saudi outcome, both 2–3 quarters away.

The single number to track: EBITDA margin in FY27 H2 and FY28. If it recovers to 24%+ by FY28 Q2, the growth + margin expansion narrative re-emerges and the stock re-rates. If it stays at 23%, growth story is capped and multiple likely compresses.

Informational and educational content only. Not investment advice.